Navigation Links
Glaucoma medications may be associated with reduced risk of death over 4-year period
Date:2/8/2010

Glaucoma patients who take medication for the condition appear to have a reduced likelihood of death, according to a report in the February issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

Glaucoma (a common condition that consists of elevated pressure in the eye, and that can lead to loss of vision) usually affects older adults, who are at risk for co-existing medical conditions that can negatively affect their survival, according to background information in the article. "In recent years, numerous studies have assessed whether glaucoma is associated with mortality," the authors write. "Few studies, however, have considered whether the medications commonly used to treat glaucoma may affect the association between glaucoma and death."

Joshua D. Stein, M.D., M.S., and colleagues at the University of Michigan, Ann Arbor, conducted a study evaluating the relationship between glaucoma medication use and death in 21,506 individuals age 40 or older (average age 60) with glaucoma or suspected glaucoma from January 2003 to December 2007 who were enrolled in a large managed care network. Glaucoma medication use was defined as filling one or more prescriptions for a 30-day or more supply of the drug during the study period. Deaths were reported by family members, employers or health care professionals and other demographic information was noted at the beginning of the study.

More than half of the patients had suspected glaucoma, the others had one or more types of glaucoma. "During the study period, 6,049 beneficiaries (28.1 percent) filled one or more prescriptions for a glaucoma medication; 2,021 individuals (9.4 percent) underwent glaucoma surgery," the authors write.

Of the 21,506 patients, 237 (1.1 percent) died during the study. When compared to those with no glaucoma medication use, those using any class of glaucoma medication had a 74 percent reduced risk of death. "This association was observed for use of a single agent alone, such as a topical beta-antagonist or a prostaglandin analogue, and for use of different combinations of drug classes," the authors write.

"Additional studies are needed to determine whether this result is best explained by a protective effect of the medications themselves or by other confounding factors, such as access to care or providers' prescribing patterns," the authors conclude. "Future investigations should explore this association further because these findings may have important clinical implications."


'/>"/>

Contact: Betsy Nisbet
bsnisbet@umich.edu
734-647-5586
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Glaucoma Drugs May Play Role in Longer Life
2. Luis Tiant and Sunridge International Partner to Provide Medical Relief in Cuba: Former Star Pitcher for the Red Sox and Yankees Leads the Fight Against Glaucoma
3. DR Vitamins, LLC Introduces Vision Clarity Carnosine Eye Drops to Treat Cataracts, Glaucoma, Dry Eye, or Other Eye Ailments
4. January is Glaucoma Awareness Month
5. Refinement of glaucoma testing, treatment expected from US, United Kingdom study
6. AUDIO from Medialink and Pfizer: Glaucoma - The Sneak Thief of Sight
7. Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic
8. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target
9. Glaucoma Tied to Gene Variants in Blacks
10. OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
11. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... La. (PRWEB) , ... July 21, 2017 , ... ... allow 4th-year medical students improve their chances of acceptance to a residency in ... those who have earned degrees outside the U.S. , According to data released ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is proud of ... her research center at Bio-Logic Aqua Research® Water Life Science®, has been released ... of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first prospective ACL ... Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain ... decline over time. The study, presented today at the American Orthopaedic Society ...
(Date:7/21/2017)... ... July 21, 2017 , ... How ... are on the rise, say researchers presenting their work at the American ... , “The combination of evaluating the patterns of change in concussion symptom presentation, ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... manufacturing network, the Company will be ceasing operations and ... Huntsville, Alabama . The closure of the facilities ... to 18 months. The Huntsville ... products and these restructuring actions are intended to better ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/17/2017)... -- MedX Holdings, Inc., the manufacturer and global distributor of ... today announced the national roll out of its MedX ... standard for the treatment of low back injuries and ... How it works: MedX ... who prescribe the MedX Home Back Machine Program for ...
Breaking Medicine Technology: